Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fenoxaprop‑ethyl is a selective, systemic, post-emergence herbicide used to control annual and perennial grass weeds in crops such as cereals, rice, soybeans, potatoes, cotton, beans, beets and other vegetables. It belongs to the aryloxy phenoxy-propionate class of herbicides. Fenoxaprop‑ethyl is rapidly absorbed by leaves and translocated throughout the plant. Its primary mechanism of action is inhibition of acetyl-CoA carboxylase (ACCase), an enzyme essential for fatty acid synthesis in grasses; this disrupts lipid metabolism leading to yellowing and death of susceptible weeds within two to three weeks after application. The compound exists as chiral R‑ and S‑isomers; the R-isomer (fenoxaprop-P) is the active form[1][4][5][8]. Developed originally by Hoechst (now part of Bayer), it has been marketed under various trade names globally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fenoxaprop-ethyl.